Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drowsy driving warnings

This article was originally published in The Tan Sheet

Executive Summary

"Warnings about medications that cause drowsiness should be made much stronger," a telephone survey for the Advocates for Highway and Auto Safety concludes. Partially funded by Schering- Plough, the survey report, released May 7, says 52% of those surveyed are "very aware" that "drowsiness in driving might be caused by people who are taking medications which may make them nod off when they are driving,"; 85% "believe it is important that people who take such [drowsiness-causing] medications should be warned specifically not to drive a car after taking them or should take other medications which help then for their condition but do not cause drowsiness." The report adds: "Obviously, if there are medications which help a condition and do not cause drowsiness, people want very much to know about them." Schering markets Claritin (loratadine), an Rx non-sedating antihistamine...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel